{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"25.3","value":"4.80"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"57.9","value":"5.26"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"51.5","value":"5.52"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"101"}],"units":"Participants"}],"description":"Progression-free survival is defined as the duration from the date of the first dose of study drug until the date of first documented evidence of progressive disease (or relapse for participants who experience CR during the study) or death due to any cause, whichever occurs first, regardless of the use of subsequent anticancer therapy. As per RECIST version 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (\\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"Full Range","groups":[{"description":"Participants received single dose of erdafitinib 10 mg tablet, orally, once daily, starting from Day 1 through Day 7 and from Day 15 through Day 21 and so on, that is 7-day on and off in each subsequent 28-day cycles starting from Cycle 1. Based on serum phosphate (PO4) levels, there was an option to up-titrate erdafitinib dose to 12 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG000","title":"Main Study: Regimen 1: Erdafitinib 10 Milligrams (mg)/ 12 mg"},{"description":"Participants received single dose of erdafitinib 6 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 8 mg, orally, once daily starting from Cycle 2 Day 1 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG001","title":"Main Study: Regimen 2: Erdafitinib 6 mg/ 8 mg"},{"description":"Participants received single dose of erdafitinib 8 mg tablet, orally, once daily, starting from Day 1 through Day 28 in each subsequent 28-day cycles starting from Cycle 1. Based on serum PO4 levels, there was an option to up-titrate erdafitinib dose to 9 mg, orally, once daily starting from Cycle 1 Day 15 until disease progression, unacceptable toxicity, or any other reason for treatment discontinuation.","id":"OG002","title":"Main Study: Regimen 3: Erdafitinib 8 mg/ 9 mg"}],"paramType":"MEDIAN","populationDescription":"The population included participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From screening up to 6 years 2 months","title":"Main Study: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}